New serologic markers of inflammatory bowel disease may be useful for differentiating between Crohn's disease and ulcerative colitis and for disease stratification.
Dr Iris Dotan and colleagues from Israel profiled sugar-binding antibodies to identify novel antiglycan antibodies that may be associated with inflammatory bowel disease (IBD).
Serum samples were obtained from patients with diagnosed Crohn's disease or ulcerative colitis and from control patients.
The research team evaluated the presence of antiglycan antibodies using either a glycan array, in 72 patients with Crohn's or 56 patients with ulcerative colitis, and 41 healthy controls.
The team used an enzyme-linked immunosorbent assay in 124 patients with Crohn's disease, 106 with ulcerative colitis, and 101 in control patients.
In addition to antibodies against mannan, antibodies to laminaribioside, and chitobioside had the highest discriminative capability between Crohn's disease and ulcerative colitis.
|Antibodies in patients suggested Crohn's diagnosis with a sensitivity of 77%|
|Inflammatory Bowel Diseases|
The researchers found that 44% of anti-Saccharomyces cerevisiae antibody-negative Crohn's disease patients were positive for antilaminaribioside or antichitobioside.
In IBD patients positive for antibodies against either laminaribioside, chitobioside, or mannan, Crohn's diagnosis was suggested with a sensitivity of 77%, and specificity of 91%.
The team noted that having at least 2 of these antibodies increased the specificity to 99%.
In Crohn's disease, higher levels of antibodies against laminaribioside or mannan were associated with small intestinal disease.
Dr Dotan's team concludes, “Antilaminaribioside and antichitobioside carbohydrate antibodies are novel serologic markers associated with Crohn's disease.”
“These antibodies may contribute to the diagnosis and improved stratification of Crohn's disease.”